- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 (NT1) - ORX750 advancing in IND-enabling studies; Clinical proof of concept data planned for 2024 BOSTON and LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced a robust set of new preclinical data from in vivo and in vitro studies of its investigational, novel orexin receptor 2 (OX2R) agonist, ORX750, that support its potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders.

-临床前数据显示，在IND启动研究中，发作性睡病1型（NT1）-ORX750的高度预测性翻译模型中低剂量ORX750具有显着活性；计划于2024年波士顿和伦敦，2023年10月25日（GLOBE NEWSWIRE）的临床概念验证数据-Centessa Pharmaceuticals plc（纳斯达克股票代码：CNTA），一家临床阶段制药公司，旨在发现和开发转型药物对于患者而言，今天宣布了一套来自其研究的体内和体外研究的强大的新临床前数据，新型食欲素受体2（OX2R）激动剂ORX750，支持其潜在的一流概况，用于治疗发作性睡病和其他睡眠-觉醒障碍。

The preclinical data will be featured today in an oral presentation by Sarah Wurts Black PhD, Head of Biology for Centessa’s Orexin Agonist Program, entitled, “ORX750, an Oral Selective Orexin Receptor 2 Agonist, Promotes Wakefulness and Reduces Cataplexy in the Orexin/Ataxin-3 Mouse,” at the World Sleep Congress in Rio De Janeiro, Brazil.

临床前数据将在Sarah Wurts Black博士（Centessa的食欲素激动剂项目生物学负责人）的口头报告中得到介绍，题为“ORX750，一种口服选择性食欲素受体2激动剂，促进觉醒并减少食欲素/Ataxin-3的猝倒症鼠标“，在巴西里约热内卢的世界睡眠大会上。

“We are very excited to share this robust preclinical dataset, which we believe shows the significant activity of low doses of ORX750 in highly predictive, translational models of narcolepsy type 1 (NT1),” said Mario Alberto Accardi PhD, President of Centessa’s Orexin Agonist Program. “The preclinical data showed ORX750 achieved maximal wake times and suppressed cataplexy at 0.1 mg/kg, the lowest oral dose tested in the DTA mouse model.

“我们非常高兴分享这个强大的临床前数据集，我们相信这些数据集显示了低剂量ORX750在高度预测性发作性睡病1型（NT1）转化模型中的重要活性，”Centessa's总裁Mario Alberto-Accardi博士说。食欲素激动剂计划。“临床前数据显示ORX750达到最大唤醒时间并抑制0.1mg/kg的猝倒，这是DTA小鼠模型中测试的最低口服剂量。

Notably, this activity was observed in both the DTA and Atax mouse models that recapitulate NT1 symptoms in humans. The data also showed ORX750 significantly increased wake time in healthy wild type mice at 1 mg/kg, the lowest oral dose tested, supporting the potential for expansion.

值得注意的是，在DTA和Atax小鼠模型中观察到这种活性，其概括了人类中的NT1症状。数据还显示ORX750以1mg/kg（测试的最低口服剂量）显着增加健康野生型小鼠的唤醒时间，支持扩张的可能性。